Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries G1 Therapeutics Inc (NQ: GTHX ) 7.130 +0.040 (+0.56%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about G1 Therapeutics Inc < Previous 1 2 Next > SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders August 15, 2024 From Halper Sadeh LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP) August 15, 2024 From Brodsky & Smith LLC Via GlobeNewswire G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX August 09, 2024 From Kahn Swick & Foti, LLC Via Business Wire SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders August 09, 2024 From Halper Sadeh LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP) August 08, 2024 From Brodsky & Smith LLC Via GlobeNewswire G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights August 08, 2024 From G1 Therapeutics Via GlobeNewswire GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders August 07, 2024 From Halper Sadeh LLC Via Business Wire Pharmacosmos Group to Acquire G1 Therapeutics August 07, 2024 From G1 Therapeutics; Pharmacosmos Via GlobeNewswire G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 July 25, 2024 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC) June 24, 2024 From G1 Therapeutics Via GlobeNewswire Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) May 28, 2024 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting May 23, 2024 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses May 22, 2024 - Jupiter Bioventures will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib for Radioprotection in the US, Europe, Japan, and All Other... From G1 Therapeutics Via GlobeNewswire G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights May 01, 2024 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib May 01, 2024 - Pepper Bio will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib in the US, Europe, Japan, and All Other Global Markets Excluding... From G1 Therapeutics Via GlobeNewswire Biotech Innovations Paving the Way in Breast Cancer Fight April 11, 2024 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END Via FinancialNewsMedia Topics Death Exposures Death Product Safety G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights February 28, 2024 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee February 12, 2024 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference January 08, 2024 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy December 05, 2023 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium November 29, 2023 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights November 01, 2023 From G1 Therapeutics Via GlobeNewswire Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) October 27, 2023 Multiple Analyses Also Describe Significant Burden of Chemotherapy-Induced Myelosuppression and Impact on Healthcare Resource Utilization in ES-SCLC From G1 Therapeutics Via GlobeNewswire G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO) October 18, 2023 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium October 16, 2023 From G1 Therapeutics Via GlobeNewswire Black Diamond Therapeutics Announces CEO Transition September 18, 2023 From Black Diamond Therapeutics, Inc Via GlobeNewswire G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights August 02, 2023 From G1 Therapeutics Via GlobeNewswire New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) July 31, 2023 From G1 Therapeutics Via GlobeNewswire Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy June 04, 2023 From G1 Therapeutics Via GlobeNewswire New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer May 16, 2023 Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events From G1 Therapeutics Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.